Scynexis announces publication of review article on ibrexafungerp

SCYNEXIS announced the publication of a review article highlighting the potential use of ibrexafungerp as a novel treatment option for invasive infections caused by opportunistic molds in the Journal of Fungi. "This review in the Journal of Fungi showcases ibrexafungerp as a potential treatment for invasive mold infections, which are a growing threat to public health, particularly in immunocompromised patients," said David Angulo, M.D., Chief Medical Officer of SCYNEXIS and lead author of the publication. "The importance of this topic is further underscored by the recently published WHO fungal priority pathogens list to guide research, development and public health action, validating the need for new antifungal agents such as ibrexafungerp, which has shown a spectrum of activity against most of the fungal pathogens in this priority list."